Canada's drug price watchdog issues decision in acne drug case
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 12/21/16 -- Patented Medicine Prices Review Board
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on December 19, 2016 relating to the medicines Differin and Differin XP, manufactured and marketed in Canada by Galderma Canada Inc. (Galderma). The Hearing Panel found that one of the three patents at issue in the proceedings pertains to Differin and ordered Galderma to provide PMPRB staff with pricing and sales information required by section 80 of the Patent Act and the Patented Medicines Regulations with respect to that medicine for the period between January 1, 2010 and March 14, 2016. The Hearing Panel dismissed PMPRB staff's application with respect to the other two patents at issue.
Quick Facts
Related Documents
- Board Order ()
Associated Links
- (Justice Canada)
- (Justice Canada)
- (Patented Medicine Prices Review Board)
Follow us on Twitter:
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
TTY (telecommunications device
for the hearing impaired)
613-957-4373
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.12.2016 - 18:25 Uhr
Sprache: Deutsch
News-ID 514360
Anzahl Zeichen: 0
contact information:
Town:
OTTAWA, ONTARIO
Kategorie:
National
Diese Pressemitteilung wurde bisher 499 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Canada's drug price watchdog issues decision in acne drug case"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
